United States Pharmaceuticals

XenoPort Inc (XNPT)

Track

Track

Ticker: XNPT Exchange: NSQ
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
No insider activity signals detected

Insider trades have not triggered unusual activity signals for this company.

Top insiders

Similar companies

View all Pharmaceuticals companies
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Flynn James E Large shareholder
Transaction date
Purchase
Price
416.56
Quantity 21,150 +17.2%
Value US$4,769,148
Flynn James E Large shareholder
Transaction date
Purchase
Price
377.94
Quantity 27,761 -46.8%
Value US$3,116,488
Flynn James E Large shareholder
Transaction date
Purchase
Price
295.99
Quantity 30,609 +45.5%
Value US$4,354,690
Flynn James E Large shareholder
Transaction date
Purchase
Price
3.92
Quantity 15,499 +0.7%
Value US$60,803
Flynn James E Large shareholder
Transaction date
Purchase
Price
3.76
Quantity 1,157,189 +74.3%
Value US$4,349,642
Flynn James E Large shareholder
Transaction date
Purchase
Price
3.76
Quantity 909,221 +74.3%
Value US$3,417,580
Flynn James E Large shareholder
Transaction date
Purchase
Price
3.96
Quantity 1,557,991 +inf%
Value US$6,166,840
Flynn James E Large shareholder
Transaction date
Purchase
Price
3.96
Quantity 1,224,136 +inf%
Value US$4,845,375
Flynn James E Large shareholder
Transaction date
Purchase
Price
4.09
Quantity 346,417 +5.5%
Value US$1,418,404
Freund John Gordon Non-Executive Director
Transaction date
Sale
Price
6.68
Quantity 909 -0.2%
Value US$6,074
Barrett Ronald W Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
7.20
Quantity 12,500 -5.8%
Value US$90,000
WIERENGA WENDALL Non-Executive Director
Transaction date
Purchase
Price
5.63
Quantity 5,000 +20.8%
Value US$28,169
RIEFLIN WILLIAM JL Non-Executive Director
Transaction date
Sale
Price
8.49
Quantity 2,500 -10.3%
Value US$21,225
RIEFLIN WILLIAM JL Non-Executive Director
Transaction date
Sale
Price
8.49
Quantity 5,592 -18.8%
Value US$47,476
RIEFLIN WILLIAM JL Non-Executive Director
Transaction date
Sale
Price
8.49
Quantity 2,918 -8.9%
Value US$24,774
Barrett Ronald W Chief Executive Officer Executive Director
Transaction date
Sale
Price
8.40
Quantity 3,000 -1.8%
Value US$25,200
Barrett Ronald W Chief Executive Officer Executive Director
Transaction date
Sale
Price
8.35
Quantity 2,000 -1.2%
Value US$16,700
Barrett Ronald W Chief Executive Officer Executive Director
Transaction date
Sale
Price
8.32
Quantity 1,015 -0.6%
Value US$8,445
BATES GREGORY T SVP, Regulatory Affairs & QA Officer
Transaction date
Sale
Price
8.35
Quantity 9,581 -31.6%
Value US$80,001
BATES GREGORY T SVP, Regulatory Affairs & QA Officer
Transaction date
Sale
Price
8.35
Quantity 4,585 -18.1%
Value US$38,285
Barrett Ronald W Chief Executive Officer Executive Director
Transaction date
Sale
Price
8.30
Quantity 1,000 -0.6%
Value US$8,303
Bosko Gianna M SVP, CLO and Secretary Officer
Transaction date
Sale
Price
8.40
Quantity 20,000 -20.6%
Value US$168,000
Bosko Gianna M SVP, CLO and Secretary Officer
Transaction date
Sale
Price
8.45
Quantity 21,348 -21.7%
Value US$180,418
Bosko Gianna M SVP, CLO and Secretary Officer
Transaction date
Sale
Price
8.50
Quantity 7,399 -8.8%
Value US$62,897
Bosko Gianna M SVP, CLO and Secretary Officer
Transaction date
Sale
Price
8.50
Quantity 11,253 -12.7%
Value US$95,658
BATES GREGORY T SVP, Regulatory Affairs & QA Officer
Transaction date
Sale
Price
5.26
Quantity 5,612 -21.3%
Value US$29,519
Freund John Gordon Non-Executive Director
Transaction date
Purchase
Price
3.93
Quantity 12,500 +123.4%
Value US$49,164
FRIEDMAN CATHY Non-Executive Director
Transaction date
Purchase
Price
3.92
Quantity 2,600 +inf%
Value US$10,179
WIERENGA WENDALL Non-Executive Director
Transaction date
Purchase
Price
3.99
Quantity 10,000 +71.4%
Value US$39,900
FENTON DENNIS M Non-Executive Director
Transaction date
Purchase
Price
4.02
Quantity 3,000 +30.0%
Value US$12,046
Barrett Ronald W Chief Executive Officer Executive Director
Transaction date
Purchase
Price
3.75
Quantity 2,600 +1.5%
Value US$9,745
Freund John Gordon Non-Executive Director
Transaction date
Purchase
Price
3.72
Quantity 9,500 +81.2%
Value US$35,354
MARIO ERNEST Non-Executive Director
Transaction date
Purchase
Price
3.73
Quantity 30,000 +55.8%
Value US$111,978
Freund John Gordon Non-Executive Director
Transaction date
Purchase
Price
3.75
Quantity 5,500 +88.7%
Value US$20,623
BERNS PAUL L Non-Executive Director
Transaction date
Planned sale
Price
3.66
Quantity 2,500 -33.3%
Value US$9,150
BATES GREGORY T SVP, Regulatory Affairs & QA Officer
Transaction date
Sale
Price
5.35
Quantity 7,500 -31.2%
Value US$40,125
MARIO ERNEST Non-Executive Director
Transaction date
Purchase
Price
5.49
Quantity 20,000 +200.0%
Value US$109,800
MARIO ERNEST Non-Executive Director
Transaction date
Purchase
Price
8.50
Quantity 10,000 +inf%
Value US$84,983
RIEFLIN WILLIAM JL Non-Executive Director
Transaction date
Purchase
Price
3.86
Quantity 10,000 +3.7%
Value US$38,580
RIEFLIN WILLIAM JL Non-Executive Director
Transaction date
Purchase
Price
4.44
Quantity 10,000 +3.8%
Value US$44,413
RIEFLIN WILLIAM JL Non-Executive Director
Transaction date
Purchase
Price
5.49
Quantity 5,000 +2.0%
Value US$27,452
FENTON DENNIS M Non-Executive Director
Transaction date
Purchase
Price
7.86
Quantity 300 +30.0%
Value US$2,358
FENTON DENNIS M Non-Executive Director
Transaction date
Purchase
Price
7.87
Quantity 35 +3.6%
Value US$275
FENTON DENNIS M Non-Executive Director
Transaction date
Purchase
Price
7.92
Quantity 100 +11.6%
Value US$792
FENTON DENNIS M Non-Executive Director
Transaction date
Purchase
Price
7.93
Quantity 100 +13.1%
Value US$793
FENTON DENNIS M Non-Executive Director
Transaction date
Purchase
Price
7.94
Quantity 765 +inf%
Value US$6,071
Cundy Kenneth C SVP, Preclinical Development Officer
Transaction date
Planned sale
Price
18.47
Quantity 100 -0.7%
Value US$1,847
Cundy Kenneth C SVP, Preclinical Development Officer
Transaction date
Planned sale
Price
18.43
Quantity 100 -0.7%
Value US$1,843
Cundy Kenneth C SVP, Preclinical Development Officer
Transaction date
Planned sale
Price
18.58
Quantity 100 -0.7%
Value US$1,858
Cundy Kenneth C SVP, Preclinical Development Officer
Transaction date
Planned sale
Price
18.61
Quantity 100 -0.7%
Value US$1,861
Cundy Kenneth C SVP, Preclinical Development Officer
Transaction date
Planned sale
Price
18.52
Quantity 100 -0.7%
Value US$1,852
Cundy Kenneth C SVP, Preclinical Development Officer
Transaction date
Planned sale
Price
18.50
Quantity 100 -0.6%
Value US$1,850
Cundy Kenneth C SVP, Preclinical Development Officer
Transaction date
Planned sale
Price
18.46
Quantity 100 -0.6%
Value US$1,846
Cundy Kenneth C SVP, Preclinical Development Officer
Transaction date
Planned sale
Price
18.39
Quantity 100 -0.6%
Value US$1,839
Cundy Kenneth C SVP, Preclinical Development Officer
Transaction date
Planned sale
Price
18.32
Quantity 100 -0.6%
Value US$1,832
Cundy Kenneth C SVP, Preclinical Development Officer
Transaction date
Planned sale
Price
18.30
Quantity 100 -0.6%
Value US$1,830
Cundy Kenneth C SVP, Preclinical Development Officer
Transaction date
Planned sale
Price
18.36
Quantity 200 -1.2%
Value US$3,672
Cundy Kenneth C SVP, Preclinical Development Officer
Transaction date
Planned sale
Price
18.49
Quantity 200 -1.2%
Value US$3,698
Cundy Kenneth C SVP, Preclinical Development Officer
Transaction date
Planned sale
Price
18.57
Quantity 100 -0.6%
Value US$1,857
Cundy Kenneth C SVP, Preclinical Development Officer
Transaction date
Planned sale
Price
18.60
Quantity 200 -1.2%
Value US$3,720
Cundy Kenneth C SVP, Preclinical Development Officer
Transaction date
Planned sale
Price
18.79
Quantity 30 -0.2%
Value US$564
Cundy Kenneth C SVP, Preclinical Development Officer
Transaction date
Planned sale
Price
18.80
Quantity 2 -0.0%
Value US$38
Cundy Kenneth C SVP, Preclinical Development Officer
Transaction date
Planned sale
Price
18.81
Quantity 68 -0.4%
Value US$1,279
Cundy Kenneth C SVP, Preclinical Development Officer
Transaction date
Planned sale
Price
18.68
Quantity 100 -0.6%
Value US$1,868
Cundy Kenneth C SVP, Preclinical Development Officer
Transaction date
Planned sale
Price
18.72
Quantity 100 -0.6%
Value US$1,872
Cundy Kenneth C SVP, Preclinical Development Officer
Transaction date
Planned sale
Price
19.20
Quantity 100 -0.7%
Value US$1,920
Cundy Kenneth C SVP, Preclinical Development Officer
Transaction date
Planned sale
Price
19.17
Quantity 100 -0.7%
Value US$1,917
Cundy Kenneth C SVP, Preclinical Development Officer
Transaction date
Planned sale
Price
19.52
Quantity 100 -0.7%
Value US$1,952
Cundy Kenneth C SVP, Preclinical Development Officer
Transaction date
Planned sale
Price
19.36
Quantity 100 -0.7%
Value US$1,936
Cundy Kenneth C SVP, Preclinical Development Officer
Transaction date
Planned sale
Price
19.26
Quantity 32 -0.2%
Value US$616
Cundy Kenneth C SVP, Preclinical Development Officer
Transaction date
Planned sale
Price
19.25
Quantity 268 -1.8%
Value US$5,159
Cundy Kenneth C SVP, Preclinical Development Officer
Transaction date
Planned sale
Price
19.28
Quantity 200 -1.4%
Value US$3,856
Cundy Kenneth C SVP, Preclinical Development Officer
Transaction date
Planned sale
Price
19.23
Quantity 100 -0.7%
Value US$1,923
Cundy Kenneth C SVP, Preclinical Development Officer
Transaction date
Planned sale
Price
19.22
Quantity 200 -1.3%
Value US$3,844
Cundy Kenneth C SVP, Preclinical Development Officer
Transaction date
Planned sale
Price
19.27
Quantity 100 -0.7%
Value US$1,927
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2016-02-23 2016-02-19 B Purchase Flynn James E Large shareholder
21,150 +17.2%
416.56
US$4,769,148 		21,150 +17.2% 416.56 US$4,769,148
2016-02-23 2016-02-19 B Purchase Flynn James E Large shareholder
27,761 -46.8%
377.94
US$3,116,488 		27,761 -46.8% 377.94 US$3,116,488
2016-02-16 2016-02-12 B Purchase Flynn James E Large shareholder
30,609 +45.5%
295.99
US$4,354,690 		30,609 +45.5% 295.99 US$4,354,690
2016-02-16 2016-02-12 B Purchase Flynn James E Large shareholder
15,499 +0.7%
3.92
US$60,803 		15,499 +0.7% 3.92 US$60,803
2016-02-16 2016-02-11 B Purchase Flynn James E Large shareholder
1,157,189 +74.3%
3.76
US$4,349,642 		1,157,189 +74.3% 3.76 US$4,349,642
2016-02-16 2016-02-11 B Purchase Flynn James E Large shareholder
909,221 +74.3%
3.76
US$3,417,580 		909,221 +74.3% 3.76 US$3,417,580
2016-02-16 2016-02-11 B Purchase Flynn James E Large shareholder
1,557,991 +inf%
3.96
US$6,166,840 		1,557,991 +inf% 3.96 US$6,166,840
2016-02-16 2016-02-11 B Purchase Flynn James E Large shareholder
1,224,136 +inf%
3.96
US$4,845,375 		1,224,136 +inf% 3.96 US$4,845,375
2016-01-22 2016-01-20 B Purchase Flynn James E Large shareholder
346,417 +5.5%
4.09
US$1,418,404 		346,417 +5.5% 4.09 US$1,418,404
2015-11-13 2015-11-11 S Sale Freund John Gordon Non-Executive Director
909 -0.2%
6.68
US$6,074 		909 -0.2% 6.68 US$6,074
2015-07-15 2015-07-15 PlS Planned sale Barrett Ronald W

Chief Executive Officer

Executive Director
12,500 -5.8%
7.20
US$90,000 		12,500 -5.8% 7.20 US$90,000
2015-05-12 2015-05-11 B Purchase WIERENGA WENDALL Non-Executive Director
5,000 +20.8%
5.63
US$28,169 		5,000 +20.8% 5.63 US$28,169
2014-12-12 2014-12-10 S Sale RIEFLIN WILLIAM JL Non-Executive Director
2,500 -10.3%
8.49
US$21,225 		2,500 -10.3% 8.49 US$21,225
2014-12-12 2014-12-10 S Sale RIEFLIN WILLIAM JL Non-Executive Director
5,592 -18.8%
8.49
US$47,476 		5,592 -18.8% 8.49 US$47,476
2014-12-12 2014-12-10 S Sale RIEFLIN WILLIAM JL Non-Executive Director
2,918 -8.9%
8.49
US$24,774 		2,918 -8.9% 8.49 US$24,774
2014-12-10 2014-12-08 S Sale Barrett Ronald W

Chief Executive Officer

Executive Director
3,000 -1.8%
8.40
US$25,200 		3,000 -1.8% 8.40 US$25,200
2014-12-10 2014-12-08 S Sale Barrett Ronald W

Chief Executive Officer

Executive Director
2,000 -1.2%
8.35
US$16,700 		2,000 -1.2% 8.35 US$16,700
2014-12-10 2014-12-08 S Sale Barrett Ronald W

Chief Executive Officer

Executive Director
1,015 -0.6%
8.32
US$8,445 		1,015 -0.6% 8.32 US$8,445
2014-12-10 2014-12-08 S Sale BATES GREGORY T

SVP, Regulatory Affairs & QA

Officer
9,581 -31.6%
8.35
US$80,001 		9,581 -31.6% 8.35 US$80,001
2014-12-10 2014-12-08 S Sale BATES GREGORY T

SVP, Regulatory Affairs & QA

Officer
4,585 -18.1%
8.35
US$38,285 		4,585 -18.1% 8.35 US$38,285
2014-12-10 2014-12-08 S Sale Barrett Ronald W

Chief Executive Officer

Executive Director
1,000 -0.6%
8.30
US$8,303 		1,000 -0.6% 8.30 US$8,303
2014-12-08 2014-12-05 S Sale Bosko Gianna M

SVP, CLO and Secretary

Officer
20,000 -20.6%
8.40
US$168,000 		20,000 -20.6% 8.40 US$168,000
2014-12-08 2014-12-05 S Sale Bosko Gianna M

SVP, CLO and Secretary

Officer
21,348 -21.7%
8.45
US$180,418 		21,348 -21.7% 8.45 US$180,418
2014-12-08 2014-12-04 S Sale Bosko Gianna M

SVP, CLO and Secretary

Officer
7,399 -8.8%
8.50
US$62,897 		7,399 -8.8% 8.50 US$62,897
2014-12-08 2014-12-04 S Sale Bosko Gianna M

SVP, CLO and Secretary

Officer
11,253 -12.7%
8.50
US$95,658 		11,253 -12.7% 8.50 US$95,658
2014-09-10 2014-09-09 S Sale BATES GREGORY T

SVP, Regulatory Affairs & QA

Officer
5,612 -21.3%
5.26
US$29,519 		5,612 -21.3% 5.26 US$29,519
2014-06-04 2014-06-03 B Purchase Freund John Gordon Non-Executive Director
12,500 +123.4%
3.93
US$49,164 		12,500 +123.4% 3.93 US$49,164
2014-05-27 2014-05-27 B Purchase FRIEDMAN CATHY Non-Executive Director
2,600 +inf%
3.92
US$10,179 		2,600 +inf% 3.92 US$10,179
2014-05-27 2014-05-27 B Purchase WIERENGA WENDALL Non-Executive Director
10,000 +71.4%
3.99
US$39,900 		10,000 +71.4% 3.99 US$39,900
2014-05-27 2014-05-27 B Purchase FENTON DENNIS M Non-Executive Director
3,000 +30.0%
4.02
US$12,046 		3,000 +30.0% 4.02 US$12,046
2014-05-28 2014-05-23 B Purchase Barrett Ronald W

Chief Executive Officer

Executive Director
2,600 +1.5%
3.75
US$9,745 		2,600 +1.5% 3.75 US$9,745
2014-05-27 2014-05-23 B Purchase Freund John Gordon Non-Executive Director
9,500 +81.2%
3.72
US$35,354 		9,500 +81.2% 3.72 US$35,354
2014-05-27 2014-05-23 B Purchase MARIO ERNEST Non-Executive Director
30,000 +55.8%
3.73
US$111,978 		30,000 +55.8% 3.73 US$111,978
2014-05-27 2014-05-22 B Purchase Freund John Gordon Non-Executive Director
5,500 +88.7%
3.75
US$20,623 		5,500 +88.7% 3.75 US$20,623
2014-05-16 2014-05-15 PlS Planned sale BERNS PAUL L Non-Executive Director
2,500 -33.3%
3.66
US$9,150 		2,500 -33.3% 3.66 US$9,150
2013-06-17 2013-06-14 S Sale BATES GREGORY T

SVP, Regulatory Affairs & QA

Officer
7,500 -31.2%
5.35
US$40,125 		7,500 -31.2% 5.35 US$40,125
2013-05-23 2013-05-22 B Purchase MARIO ERNEST Non-Executive Director
20,000 +200.0%
5.49
US$109,800 		20,000 +200.0% 5.49 US$109,800
2012-08-09 2012-08-09 B Purchase MARIO ERNEST Non-Executive Director
10,000 +inf%
8.50
US$84,983 		10,000 +inf% 8.50 US$84,983
2011-12-16 2011-12-16 B Purchase RIEFLIN WILLIAM JL Non-Executive Director
10,000 +3.7%
3.86
US$38,580 		10,000 +3.7% 3.86 US$38,580
2011-11-22 2011-11-21 B Purchase RIEFLIN WILLIAM JL Non-Executive Director
10,000 +3.8%
4.44
US$44,413 		10,000 +3.8% 4.44 US$44,413
2011-11-09 2011-11-07 B Purchase RIEFLIN WILLIAM JL Non-Executive Director
5,000 +2.0%
5.49
US$27,452 		5,000 +2.0% 5.49 US$27,452
2010-11-12 2010-11-12 B Purchase FENTON DENNIS M Non-Executive Director
300 +30.0%
7.86
US$2,358 		300 +30.0% 7.86 US$2,358
2010-11-12 2010-11-12 B Purchase FENTON DENNIS M Non-Executive Director
35 +3.6%
7.87
US$275 		35 +3.6% 7.87 US$275
2010-11-12 2010-11-12 B Purchase FENTON DENNIS M Non-Executive Director
100 +11.6%
7.92
US$792 		100 +11.6% 7.92 US$792
2010-11-12 2010-11-12 B Purchase FENTON DENNIS M Non-Executive Director
100 +13.1%
7.93
US$793 		100 +13.1% 7.93 US$793
2010-11-12 2010-11-12 B Purchase FENTON DENNIS M Non-Executive Director
765 +inf%
7.94
US$6,071 		765 +inf% 7.94 US$6,071
2010-02-04 2010-02-01 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
100 -0.7%
18.47
US$1,847 		100 -0.7% 18.47 US$1,847
2010-02-04 2010-02-01 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
100 -0.7%
18.43
US$1,843 		100 -0.7% 18.43 US$1,843
2010-02-04 2010-02-01 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
100 -0.7%
18.58
US$1,858 		100 -0.7% 18.58 US$1,858
2010-02-04 2010-02-01 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
100 -0.7%
18.61
US$1,861 		100 -0.7% 18.61 US$1,861
2010-02-04 2010-02-01 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
100 -0.7%
18.52
US$1,852 		100 -0.7% 18.52 US$1,852
2010-02-04 2010-02-01 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
100 -0.6%
18.50
US$1,850 		100 -0.6% 18.50 US$1,850
2010-02-04 2010-02-01 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
100 -0.6%
18.46
US$1,846 		100 -0.6% 18.46 US$1,846
2010-02-04 2010-02-01 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
100 -0.6%
18.39
US$1,839 		100 -0.6% 18.39 US$1,839
2010-02-04 2010-02-01 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
100 -0.6%
18.32
US$1,832 		100 -0.6% 18.32 US$1,832
2010-02-04 2010-02-01 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
100 -0.6%
18.30
US$1,830 		100 -0.6% 18.30 US$1,830
2010-02-04 2010-02-01 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
200 -1.2%
18.36
US$3,672 		200 -1.2% 18.36 US$3,672
2010-02-04 2010-02-01 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
200 -1.2%
18.49
US$3,698 		200 -1.2% 18.49 US$3,698
2010-02-04 2010-02-01 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
100 -0.6%
18.57
US$1,857 		100 -0.6% 18.57 US$1,857
2010-02-04 2010-02-01 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
200 -1.2%
18.60
US$3,720 		200 -1.2% 18.60 US$3,720
2010-02-04 2010-02-01 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
30 -0.2%
18.79
US$564 		30 -0.2% 18.79 US$564
2010-02-04 2010-02-01 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
2 -0.0%
18.80
US$38 		2 -0.0% 18.80 US$38
2010-02-04 2010-02-01 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
68 -0.4%
18.81
US$1,279 		68 -0.4% 18.81 US$1,279
2010-02-04 2010-02-01 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
100 -0.6%
18.68
US$1,868 		100 -0.6% 18.68 US$1,868
2010-02-04 2010-02-01 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
100 -0.6%
18.72
US$1,872 		100 -0.6% 18.72 US$1,872
2010-01-06 2010-01-04 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
100 -0.7%
19.20
US$1,920 		100 -0.7% 19.20 US$1,920
2010-01-06 2010-01-04 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
100 -0.7%
19.17
US$1,917 		100 -0.7% 19.17 US$1,917
2010-01-06 2010-01-04 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
100 -0.7%
19.52
US$1,952 		100 -0.7% 19.52 US$1,952
2010-01-06 2010-01-04 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
100 -0.7%
19.36
US$1,936 		100 -0.7% 19.36 US$1,936
2010-01-06 2010-01-04 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
32 -0.2%
19.26
US$616 		32 -0.2% 19.26 US$616
2010-01-06 2010-01-04 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
268 -1.8%
19.25
US$5,159 		268 -1.8% 19.25 US$5,159
2010-01-06 2010-01-04 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
200 -1.4%
19.28
US$3,856 		200 -1.4% 19.28 US$3,856
2010-01-06 2010-01-04 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
100 -0.7%
19.23
US$1,923 		100 -0.7% 19.23 US$1,923
2010-01-06 2010-01-04 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
200 -1.3%
19.22
US$3,844 		200 -1.3% 19.22 US$3,844
2010-01-06 2010-01-04 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
100 -0.7%
19.27
US$1,927 		100 -0.7% 19.27 US$1,927
Explore more

More insider trading research around XenoPort Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Pharmaceuticals companies with insider activity
Insider trading in North America